115 related articles for article (PubMed ID: 8383627)
1. Natural killer cell activity and progression-free survival in ovarian cancer.
Garzetti GG; Cignitti M; Ciavattini A; Fabris N; Romanini C
Gynecol Obstet Invest; 1993; 35(2):118-20. PubMed ID: 8383627
[TBL] [Abstract][Full Text] [Related]
2. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma.
Kikuchi Y; Oomori K; Kizawa I; Kato K
Jpn J Clin Oncol; 1985 Jun; 15(2):377-83. PubMed ID: 3839542
[TBL] [Abstract][Full Text] [Related]
3. An assessment of sequential measurements of immune complex levels in ovarian cancer patients with respect to clinical progress.
Mooney NA; Townsend PA; Wiltshaw E; Evans DG; Shanti-Raju K; Poulton TA
Gynecol Oncol; 1983 Apr; 15(2):207-13. PubMed ID: 6299906
[TBL] [Abstract][Full Text] [Related]
4. Clinical remission criteria for epithelial carcinoma of the ovary.
Morikawa Y; Kawai M; Kano T; Kikkawa F; Oguchi H; Nakashima N; Ishizuka T; Furuhashi Y; Hattori SE; Kuzuya K
Gynecol Oncol; 1993 Mar; 48(3):342-8. PubMed ID: 7681806
[TBL] [Abstract][Full Text] [Related]
5. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
[TBL] [Abstract][Full Text] [Related]
6. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study.
Bertelsen K
Gynecol Oncol; 1990 Aug; 38(2):203-9. PubMed ID: 2167280
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
Hunter VJ; Daly L; Helms M; Soper JT; Berchuck A; Clarke-Pearson DL; Bast RC
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1164-7. PubMed ID: 2171337
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
[TBL] [Abstract][Full Text] [Related]
9. Cellular immunologic responsiveness to extracts of ovarian epithelial tumors.
Melnick H; Barber HR
Gynecol Oncol; 1975 Mar; 3(1):77-86. PubMed ID: 168133
[No Abstract] [Full Text] [Related]
10. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation.
Garzetti GG; Ciavattini A; Muzzioli M; Romanini C
Cancer; 1999 May; 85(10):2226-31. PubMed ID: 10326702
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
Massacesi C; Bascioni R; Cellerino R; Scartozzi M; Bracci R; Alessandroni P; Antognoli S; Ciavattini A; De Nictolis M; Piga A
J Exp Clin Cancer Res; 2000 Mar; 19(1):13-6. PubMed ID: 10840930
[TBL] [Abstract][Full Text] [Related]
13. Endometrioid carcinoma of the ovary. Retrospective study.
Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Cignitti M; Tranquilli AL; Romanini C
Eur J Gynaecol Oncol; 1993; 14(1):51-5. PubMed ID: 8472733
[TBL] [Abstract][Full Text] [Related]
14. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy.
Benedetti Panici P; Scambia G; Greggi S; Salerno G; Cento R; Mancuso S
Oncology; 1990; 47(4):296-8. PubMed ID: 1694980
[TBL] [Abstract][Full Text] [Related]
16. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
[TBL] [Abstract][Full Text] [Related]
17. Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide.
Mazzei T; Bonazza M; Amunni G; Scarselli G; Branconi F; Massi GB
Chemioterapia; 1984 Feb; 3(1):10-5. PubMed ID: 6535650
[TBL] [Abstract][Full Text] [Related]
18. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
19. Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital.
Linasmita V; Wilailak S; Srisupundit S; Tangtrakul S; Bullangpoti S; Israngura N
J Med Assoc Thai; 1998 Jan; 81(1):10-6. PubMed ID: 9470316
[TBL] [Abstract][Full Text] [Related]
20. [Clinical studies on malignant ovarian tumor--with special reference to therapy and prognosis of epithelial ovarian tumor].
Iwasawa H; Sekiya S; Kaihou T; Takamizawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Apr; 36(4):525-30. PubMed ID: 6325559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
